AN INVESTIGATION OF THE DOSE PROPORTIONALITY OF DEFLAZACORT PHARMACOKINETICS
| Autor: | Scott J. Weir, Vijay O. Bhargava, Niranjan Rao, Donald L. Reynolds, Mark G. Eller |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry medicine.drug_class Cmax Pharmaceutical Science General Medicine Deflazacort Endocrinology Dose proportionality Pharmacokinetics Oral administration Internal medicine Medicine Corticosteroid Pharmacology (medical) business Active metabolite medicine.drug |
| Zdroj: | Biopharmaceutics & Drug Disposition. 17:753-760 |
| ISSN: | 1099-081X 0142-2782 |
| DOI: | 10.1002/(sici)1099-081x(199612)17:9<753::aid-bdd988>3.0.co;2-d |
| Popis: | The dose proportionality of deflazacort was assessed following single-dose oral administration at doses of 3, 6, and 36 mg to 24 healthy young adult volunteers. The active metabolite of deflazacort (21-desacetyl deflazacort) was monitored in plasma using a sensitive, semi-microbore liquid chromatographic method. Cmax averaged 10.4 +/- 5.0, 19.8 +/- 7.5, and 132.6 +/- 52.5 ng mL-1 for the 3, 6, and 36 mg doses, respectively. AUC(0-infinity) averaged 38.5 +/- 37.1, 64.9 +/- 20.8, and 411.7 +/- 148.5 ng h mL-1 for the same three doses, respectively. Elimination half-life ranged from 1.9 +/- 0.5 h at the 6 mg dose to 2.4 +/- 1.5 h at the 36 mg dose. Regression analyses of dose versus Cmax and AUC(0-infinity) yielded intercepts which were not significantly different from zero (p > 0.05) and slopes which were significant (p 0.05). These data indicate that deflazacort exhibits dose-proportional pharmacokinetics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text